NCT05496192View on ClinicalTrials.gov

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2023

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2026

Conditions
MelanomaUrothelial Carcinoma
Interventions
DRUG

Nivolumab/rHuPH20

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (3)

10117

Local Institution - 0001, Berlin

41013

Local Institution - 0002, Seville

45136

Local Institution - 0020, Essen

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY